| | | |   | | | | By Jason Mast Sickle Cell Foundation of Georgia/CDC After overlooking sickle cell for decades, companies are spending billions in pursuit of new drugs that might help patients around the world. Read More | | By Jason Mast Lee Klafczynski for STAT A new drug runs into red tape from insurers, a long history of bias against sickle-cell patients, and debate over data. Read More | | By Rachel Cohrs and Sarah Owermohle Andrew Harnik/AP A sweeping new deal would ease Medicare pay cuts to doctors, make major changes to Medicaid policy, and aim to prepare for future pandemics. Read More | | Sponsored Insight by Pfizer Blood disorder toll underscores a need for more innovation Millions of people around the world suffer from blood disorders today, which is why scientists are doubling down on their efforts to develop effective treatments and life-saving medical breakthroughs. Medical experts from around the globe will convene in New Orleans this month to share research and medical advances at the annual American Society of Hematology meeting. Among them will be more than 30 abstracts from Pfizer, which has six FDA-approved blood cancer medicines. Learn more about its advancements in blood disorder treatment. | | By Adam Feuerstein Hyacinth Empinado/STAT Nods to the CEOs behind some of this year's biggest biopharma deals and most exciting new drug treatments. Read More | |
No comments